Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed neuroendocrine tumor OR characteristic radiological findings of neuroendocrine tumor with raised hormone levels in plasma or urine meeting any of the following criteria:
• •* Primary disease in gut with liver metastases (with or without hormone secretion)
• •* Primary disease in lung with liver or abdominal metastases (with or without hormone secretion)
• •* Primary disease in pancreas with or without metastases (with or without hormone secretion)
• •PATIENT CHARACTERISTICS:
• •Any Karnofsky performance status allowed
• •Life expectancy ≥ 3 months
• •Able to understand the questionnaire language
• •Mentally fit to complete questionnaire
• •No psychological, familial, sociological, or geographical condition that would limit study compliance
• •No other concurrent malignancies except basal cell carcinoma of the skin
• •PRIOR CONCURRENT THERAPY:
• •More than 2 months since prior somatostatin analogue or interferon therapy (somatostatin therapy stratum)
• •* Concurrent somatostatin analogue and/or interferon therapy allowed if dose stable over the past month
• •More than 6 months since prior radionuclide therapy or systemic chemotherapy (radionuclide or systemic chemotherapy stratum)
• •More than 6 months since prior ablative therapies (ablative therapy stratum)
• •No concurrent participation in other quality of life studies